Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward

Dexamethasone improves clinical outcomes in COVID-19 patients requiring supplementary oxygen. We investigated possible mechanisms of action by comparing sixteen plasma host response biomarkers in general ward patients before and after implementation of dexamethasone as standard of care. 48 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: de Brabander, Justin, Michels, Erik H. A., van Linge, Christine C. A., Chouchane, Osoul, Douma, Renée A., Reijnders, Tom D. Y., Schuurman, Alex R., van Engelen, Tjitske S. R., Wiersinga, W. Joost, van der Poll, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163524/
https://www.ncbi.nlm.nih.gov/pubmed/35659223
http://dx.doi.org/10.1186/s12931-022-02060-3
Descripción
Sumario:Dexamethasone improves clinical outcomes in COVID-19 patients requiring supplementary oxygen. We investigated possible mechanisms of action by comparing sixteen plasma host response biomarkers in general ward patients before and after implementation of dexamethasone as standard of care. 48 patients without and 126 patients with dexamethasone treatment were sampled within 48 h of admission. Endothelial cell and coagulation activation biomarkers were comparable. Dexamethasone treatment was associated with lower plasma interleukin (IL)-6 and IL-1 receptor antagonist levels, whilst other inflammation parameters were not affected. These data argue against modification of vascular-procoagulant responses as an early mechanism of action of dexamethasone in COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02060-3.

Ejemplares similares